Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antioxidant
    (1)
  • NMDAR
    (1)
  • Potassium Channel
    (1)
  • iGluR
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

neuron injury

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | Inhibitors_Agonists
  • Natural Products
    1
    TargetMol | Natural_Products
  • Recombinant Protein
    7
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
5,7-Dichlorokynurenic acid
5,7-dichlorokynurenic acid sodium, 5,7-DCKA
T22517131123-76-7
5,7-Dichlorokynurenic acid (5,7-dichlorokynurenic acid sodium) is an NMDA receptor antagonist.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TREK inhibitor-3
T2060653023854-95-4
TREK inhibitor-3 (Cpd8l) is a selective inhibitor of TREK-1 that can cross the blood-brain barrier, with an IC50 of 0.81 μM. It offers neuroprotective effects by significantly reducing cortical neuron death induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and alleviating brain injury in middle cerebral artery occlusion/reperfusion (MCAO/R) model mice. TREK inhibitor-3 is utilized in ischemic stroke research.
  • Inquiry Price
10-14 weeks
Size
QTY
Rasagiline-13C3 (mesylate)
Rasagiline-13C3 (mesylate)
T369031391052-18-8
Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo(ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease. 1.Youdim, M.B.H., Gross, A., and Finberg, J.P.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBrit. J. Pharmacol.132(2)500-506(2001) 2.Youdim, M.B.H., and Weinstock, M.Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]Cell. Mol. Neurobiol.21(6)555-573(2001) 3.Kang, S.S., Ahn, E.H., Zhang, Z., et al.α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's diseaseEMBO J.37(12)e98878(2018)
  • $1,110
35 days
Size
QTY
3'-Methoxypuerarin
3'- Methoxy Puerarin
T4S2084117047-07-1
3'-Methoxypuerarin shows neuron protection activity, it can protect hippocampal neurons against ischemia/reperfusion injury by inhibiting apoptosis. 3'-Methoxypuerarin(3'- Methoxy Puerarin) has antioxidant activities, it shows ONOO(-) scavenging activity and weak NO· and O(2)(-) scavenging activities.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited